申请人:Syntex (U.S.A.) Inc.
公开号:US05158949A1
公开(公告)日:1992-10-27
Compounds of formula (I): ##STR1## wherein n is 2 or 3; p is 0, 1 or 2; q is 0, 1 or 2; X is oxygen or S(O).sub.t where t is 0, 1 or 2; each R.sup.1 is independently halo, lower alkyl, lower alkoxy, or trifluoromethyl; each R.sup.2 is independently halo or lower alkyl; R.sup.3 is nitro or --N(R.sup.5)R.sup.6 where R.sup.5 is hydrogen or lower alkyl; R.sup.6 is hydrogen lower alkyl, lower alkylsulfonyl or --C(Y)R.sup.7 where Y is oxygen or sulfur and R.sup.7 is hydrogen, lower alkyl, lower alkoxy or --N(R.sup.8)R.sup.9 where R.sup.8 is hydrogen or lower alkyl and R.sup.9 is hydrogen, lower alkyl or lower alkoxycarbonyl; or R.sup.5 and R.sup.6 together with N is pyrrolidino, piperidino, morpholino, thiomorpholino or piperazino, wherein the piperazino is optionally substituted at the 4-position by --N(O)R.sup.10 where R.sup.10 is hydrogen, lower alkyl, lower alkoxy or amino; and R.sup.4 is hydrogen or lower alkyl, as single stereoisomers or as mixtures thereof; and their pharmaceutically acceptable salts, are useful in treating disease-states characterized by hypercholesterolemia.
化合物的式子(I): ##STR1## 其中n为2或3; p为0,1或2; q为0,1或2; X为氧或S(O).sub.t,其中t为0,1或2; 每个R.sup.1独立地为卤素,低烷基,低烷氧基或三氟甲基; 每个R.sup.2独立地为卤素或低烷基; R.sup.3为硝基或--N(R.sup.5)R.sup.6,其中R.sup.5为氢或低烷基; R.sup.6为氢,低烷基,低烷基磺酰基或--C(Y)R.sup.7,其中Y为氧或硫,R.sup.7为氢,低烷基,低烷氧基或--N(R.sup.8)R.sup.9,其中R.sup.8为氢或低烷基,R.sup.9为氢,低烷基或低烷氧羰基; 或者R.sup.5和R.sup.6与N一起形成吡咯烷基,哌啶基,吗啉基,硫代吗啉基或哌嗪基,其中哌嗪基在4位上可以选择性地被--N(O)R.sup.10取代,其中R.sup.10为氢,低烷基,低烷氧基或氨基; R.sup.4为氢或低烷基,作为单一立体异构体或其混合物; 以及它们的药学上可接受的盐,在治疗以高胆固醇血症为特征的疾病状态方面有用。